Optimal adherence to CML therapy is of key importance to maximize treatment effectiveness. Two clinical studies (ADAGIO and Hammersmith) have proven a clear correlation between adherence and achieving optimal treatment response and have revealed that non-adherence is common in CML patients (Marin et al. in J Clin Oncol 28(24):2381-2388, 2010, Noens et al. in Haematologica 99(33):437-447, 2014). The aim of this study is to assess the extent of suboptimal adherence and to investigate motivations and behavioural patterns of adherence in a worldwide patient sample. Questionnaires were provided by the CML Advocates Network and were filled in by patients online and offline. Patient characteristics, treatment and motivations were collected. Adherence was assessed by the 8-item Morisky Medication Adherence scale. Logistic regression models were fitted to investigate the influence of different factors on adherence. Overall, 2 546 questionnaires from 63 countries and 79 CML patient organisations were evaluable. 32.7% of participants were highly adherent, 46.5% were in the medium and 20.7% in the low adherence group. Factors increasing the probability of being in the high adherence group are older age, male sex, management of side effects, only one tablet per day and feeling well informed about CML by the doctor. More than 2 years since diagnosis were significantly lowering the chance as was the use of reminding tools. Living arrangements, multiple medication and personal payment obligations increased the probability to be at least in the medium adherent group. This is the most comprehensive study conducted to date to gain knowledge about factors causing non-adherence in CML. Better information on the disease, medication and management of side effects, supported by haematologists, is key to improve adherence.

Diagnoza CML Prague Czech Republic

Gruppo AIL Pazienti Leucemia Mieloide Cronica Rome Italy

Institute for Medical Information Sciences Biometry and Epidemiology Ludwig Maximilians Universitaet Munich Germany

Israeli CML Patients Organization Netanya Israel

Leukaemia CARE Worcester UK

LeukaNET e 5 Riemerling Germany

Leukemia Patient Advocates Foundation Bern Switzerland

LMC France Marseille France

Münzgraben 6 P O B 453 CH 3000 Bern Switzerland

Polish Nationwide Association for CML Patients Aid Warsaw Poland

Stichting Hematon Utrecht The Netherlands

Zobrazit více v PubMed

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6): 872–884 PubMed DOI PMC

Baccarani M, Efficace F, Rosti G (2014) Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden. Haematologica 99(2):205–208 PubMed DOI PMC

Balkrishnan R (1998) Predictors of medication adherence in the elderly. Clin Ther 20(4):8 PubMed DOI

Banning M (2008) Older people and adherence with medication: a review of the literature. Int J Nurs Stud 45(10):11 PubMed DOI

Bender R, Grouven U (1998) Using binary logistic regression models for ordinal data with non-proportional odds. J Clin Epidemiol 51(10):7 PubMed DOI

Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J et al (2011) Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 29(18): 2514–2520 PubMed DOI PMC

Darkow T, Henk H, Thomas S, Feng W, Baladi J, Goldberg G et al (2007) Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 25(6):15 PubMed DOI

Dunbar-Jacob J, Mortimer-Stephens MK (2001) Treatment adherence in chronic disease. J Clin Epidemiol 54(12):S57–S60 PubMed DOI

Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL (2014) Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32(4): 306–311. PubMed DOI

Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F et al (2011) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118(17): 4554–4560 PubMed DOI

Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M et al (2012) Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer 107(6):904–909 PubMed DOI PMC

Eliasson L, Clifford S, Barber N, Marin D (2011) Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 35(5): 626–630 PubMed DOI

Gellad WF, Grenard JL, Marcum ZA (2011) A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother 9(1):12 PubMed DOI PMC

Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O et al (2003) Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 17(8):1529–1537 PubMed DOI

Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J et al (2007) Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109(11): 4686–4692 PubMed DOI

Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N et al (2011) Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29(12): 1634–1642 PubMed DOI

Hirji I, Gupta S, Goren A, Chirovsky DR, Moadel AB, Olavarria E et al (2013) Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective. Health Qual Life Outcomes 11:167 PubMed DOI PMC

Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D et al (2015) The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia 29(6):1336–1343 PubMed DOI

Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M et al (2013) Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 122(7): 1284–1292. PubMed DOI PMC

Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S et al (2015) SEER cancer statistics review, 1975–2012. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2012/

Joosten EA, DeFuentes-Merillas L, De Weert G, Sensky T, Van Der Staak C, de Jong CA (2008) Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom 77(4):219–226 PubMed DOI

Kapoor J, Agrawal N, Ahmed R, Sharma SK, Gupta A, Bhurani D (2015) Factors influencing adherence to imatinib in indian chronic myeloid leukemia patients: a cross-sectional study. Mediterr J Hematol Infect Dis 7(1): e2015013 PubMed DOI PMC

Kekale M, Talvensaari K, Koskenvesa P, Porkka K, Airaksinen M (2014) Chronic myeloid leukemia patients’ adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians. Patient Preference Adherence 8:1619–1627 PubMed DOI PMC

Le CT (1998) Applied categorical data analysis. Wiley, New York

Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381–2388 PubMed DOI PMC

Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 10(5):348–354 PubMed DOI PMC

Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z et al (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113(22): 5401–5411 PubMed DOI

Noens L, Hensen M, Kucmin-Bemelmans I, Lofgren C, Gilloteau I, Vrijens B (2014) Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica 99(3): 437–447 PubMed DOI PMC

Sabaté E (2003) Adherence to long-term therapies: evidence for action. WHO Library Cataloguing-in-Publication Data, Geneva

Vermeire E, Hearnshaw H, Van Royen P, Denekens J (2001) Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 26(5):331–342 PubMed DOI